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Abstract
Background: The L1 cell adhesion molecule (L1CAM) is potentially involved in epithelial-mesenchymal transition
(EMT). EMT marker expression is of prognostic significance in non-small cell lung cancer (NSCLC). The relevance of
L1CAM for NSCLC is unclear. We investigated the protein expression of L1CAM in a cohort of NSCLC patients.
L1CAM protein expression was correlated with clinico-pathological parameters including survival and markers of
epithelial-mesenchymal transition.
Results: L1CAM protein expression was found in 25% of squamous cell carcinomas and 24% of adenocarcinomas
and correlated with blood vessel invasion and metastasis (p < 0.05). L1CAM was an independent predictor of
survival in a multivariate analysis including pT, pN, and pM category, and tumor differentiation grade. L1CAM
expression positively correlated with vimentin, beta-catenin, and slug, but inversely with E-cadherin (all p-values <
0.05). E-cadherin expression was higher in the tumor center than in the tumor periphery, whereas L1CAM and
vimentin were expressed at the tumor-stroma interface. In L1CAM-negative A549 cells the L1CAM expression was
upregulated and matrigel invasion was increased after stimulation with TGF-beta1. In L1CAM-positive SK-LU-1 and
SK-LC-LL cells matrigel invasion was decreased after L1CAM siRNA knockdown.
Conclusions: A subset of NSCLCs with vessel tropism and increased metastasis aberrantly expresses L1CAM.
L1CAM is a novel prognostic marker for NSCLCs that is upregulated by EMT induction and appears to be
instrumental for enhanced cell invasion.
Keywords: L1 cell adhesion molecule, epithelial-mesenchymal transition, tumor-stroma interface, prognostic marker,
non-small cell lung cancer, tissue microarray
Background
The 220 kDa transmembrane glycoprotein L1CAM
belongs to the neuronal immunoglobulin superfamily of
cell adhesion molecules and was first described in neural
cell migration [1] for review see [2]. L1CAM is comprised
of six IgG-like domains and five fibronectin-type III
repeats, followed by a transmembrane region and a
highly conserved cytoplasmic tail [2,3]. L1CAM protein
expression was observed in renal cell cancer, ovarian car-
cinomas, melanoma, colon cancer, pancreatic cancer, and
small cell lung cancer [4-11]. Currently, no data of
L1CAM are available for non-small cell lung cancer
(NSCLC). Membranous L1CAM enhanced motility of
HEK293 cells by interfering with integrin-dependent sig-
naling pathways, inducing endocytosis of beta 1 integrin
[12]. L1CAM expression activated extracellular signal-
regulated kinase (Erk)-dependent gene regulation and
induced NFB activity conferring increased cell motility
and invasion [13,14].
We previously reported the prognostic importance of
epithelial-mesenchymal transition (EMT) for lung cancer
[15]. EMT is a cell biological program in which cancer
cells lose their epithelial features like E-cadherin expres-
sion and up-regulate mesenchymal proteins like vimentin
or periostin [15]. Recently, L1CAM has been linked to
EMT because protein overexpression decreased the junc-
tional expression of E-cadherin and promoted colony scat-
tering in breast carcinoma cells [16]. As a consequence of
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EMT, cancer cells acquire a fibroblastic phenotype which
enables them to detach from their lattice and to become
migratory and invasive. The EMT program is inducible by
growth factors like transforming growth factor beta1
(TGF-beta1) or hepatocyte growth factor (HGF) [17]. Sev-
eral intracellular signaling cascades are involved thereafter,
including MAPK and AKT pathways (for review see
[17-20]). In pancreatic and endometrial carcinoma cells,
L1CAM up-regulation was dependent on TGF-beta1
induction of the EMT transcriptional factor slug [9,21].
The zinc finger protein slug binds to the E-box motif of
the E-cadherin promoter thereby repressing E-cadherin
[22]. Further, L1CAM is a target gene of beta-catenin/TCF
(T-cell factor) signaling [23]. Topographically, L1CAM
was exclusively detected at the invasive front of colorectal
cancer and its knockdown reduced haptotactic motility
[23].
The present study aimed to investigate the relation-
ship between L1CAM and indicators of EMT in a large
NSCLC patient cohort as well as in NSCLC cell lines.
Further, we tested the hypothesis that L1CAM is rele-
vant for patient survival.
Results and Discussion
Results
L1CAM expression in NSCLC
L1CAM protein expression (any sum intensity > score 0)
was found in 25% of the tumors. Similarly, 25% of the
SCC and 24% of the ADCA expressed L1CAM (table 1).
An overview of L1CAM expression and clinicopathologi-
cal parameters is shown in table 1. Normal lung tissue,
endothelial cells and bronchial epithelium were negative
for L1CAM stained on whole sections (Figure 1A, B).
L1CAM expression significantly correlated with the pM1
category (p = 0.031) and with blood vessel infiltration
(p = 0.036; table 1). Examples of vessel infiltration and
blood vessel tropism are shown in Figure 1C-E. L1CAM
expression was found to be strongest at the tumor-
stroma interface (Figure 1B, F and 2A, B). Expression of
L1CAM was found to be heterogeneous in 63/468
(13.5%) of cases which was confirmed in randomly
selected cases by whole sections (Figure 1F).
L1CAM expression is correlated with poor overall and
disease free survival
In the total cohort, L1CAM expression was associated
with unfavourable OS (p < 0.001) and PFS (p < 0.001)
in univariate analysis (table 2 for OS see Figure 3). All
other EMT markers were not associated with prognosis.
The prognostic impact of L1CAM expression was inde-
pendent of pT, pN, pM and tumor grade in a multivari-
ate analysis (table 3) for both OS and PFS.
L1CAM expression is correlated with EMT markers
In the total cohort L1CAM was positively correlated
with slug, both tumoral and stromal vimentin, and
inversely with E-cadherin (table 4). L1CAM correlated
positively with cytosolic but not membranous or nuclear
beta-catenin in tumor cells (table 4). On the whole sec-
tions, L1CAM was often found at the tumor-stroma
interface (Figure 1B, F and 2A, B) and E-cadherin in the
tumor center (Figure 2A-D). Likewise, up-regulated
vimentin in tumor cells was often found at the tumor-
stroma interface and in areas away from E-cadherin
(Figure 2C). Slug was also found at the tumor-stroma
interface and inversely correlated with E-cadherin
(Figure 2D) which was significant (p-value 0.005, tau =
-0.128).
L1CAM expression in-vitro
The correlation of L1CAM expression with invasion in
the TMA analysis prompted us to study the pro-invasive
function of L1CAM in-vitro. A549 cells were treated for
7 days with 5ng/mL HGF or 10ng/mL TGF-beta1 and
an EMT like phenotype was induced (Figure 4A). By
RT-PCR analysis we found L1CAM, snail, slug, vimentin
and beta-catenin mRNA upregulated in A549 cells after
TGF-beta1 stimulation for 7 days (Figure 4B). In con-
trast, E-cadherin mRNA was downregulated in A549
cells (Figure 4B). Similar results were observed for
another lung adenocarcinoma cell line H1395 (data not
shown). On the protein level, TGF-beta1 induced
increased L1CAM, vimentin and beta-catenin expression
in A549 cells whereas E-cadherin was downregulated
(Figure 4C). In a matrigel invasion assay, TGF-beta1
treatment augmented invasion of A549 cells (Figure 4D).
The cell lines SK-LU-1 and SK-LC-LL neither showed
a change in morphology nor L1CAM induction after
TGF-beta1 stimulation (data not shown). L1CAM but
not GFP siRNA knockdown completely abrogated
L1CAM expression in SK-LU-1 and SK-LC-LL cells
(Figure 5A) and led to significantly reduced matrigel
invasion of both cell lines (SK-LU-1 p = 0.036, SK-LC-
LL p = 0.028, Figure 5B). For A549 cells a difference in
matrigel invasion was not observed after siRNA-
mediated knockdown of L1CAM (data not shown).
Discussion
In this study, we demonstrate that L1CAM protein is
expressed in NSCLC and is correlated with vessel infil-
tration, metastasis, and a poor prognosis. In-vivo data
suggests that L1CAM is involved in EMT of lung can-
cer. Further, we provide evidence that L1CAM is
involved in NSCLC cell invasion.
L1CAM expression was found in 25% of NSCLC by
immunohistochemistry, using our previously described
monoclonal anti-L1CAM antibody (clone 14.10), which
is directed to the ectodomain of L1CAM (CD171).
Three hundred fifty-three tumors with two L1CAM
negative cores were defined as negative. It cannot be ruled
out that some of these cases have L1CAM expression due
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to intratumoral heterogeneity. However, we found
L1CAM expression heterogeneity of 13.5%. In these cases,
different staining scores were observed in the two cores of
the tumor. Of these, 34 tumors had the score “0 and 1” or
“1 and 0”. These are less than 10% compared to the 353
cases that are L1CAM negative for both cores. In 10 ran-
domly chosen L1CAM negative cases identified by TMA
we did not observe focal L1CAM positivity on whole sec-
tions. Our finding of L1CAM expression in non-small cell
lung cancer is in contrast to a previous protein expression
profile study across several human tissues, which was not
able to identify L1CAM expression in NSCLC [24]. This
discrepancy is most probably due to the low case number
(10 SCC/5 ADCA) in that recent expression analysis [24].
Importantly, other studies identified L1CAM expression in
small cell lung carcinoma, in pulmonary carcinoids and in
large cell lung carcinomas [10,25]. Interestingly, a relation-
ship to prognosis was also demonstrated in large cell lung
carcinomas [25], corroborating our findings in NSCLC.
Only L1CAM was of uni- as well as multivariate prognos-
tic significance for OS and PFS among all biomarkers
tested. These data are in line with published prognostic
Table 1 L1CAM expression and clinicopathological parameters
n % L1CAM negative % L1CAM positive % p-value/
tau
Total 468 100 353 75.4 115 24.6
Age ≤64 years 227 48.5 178 78.4 49 21.6 ns
Age > 64 years 241 51.5 175 72.6 66 27.4
Male 325 69.4 243 74.8 82 25.2 ns
Female 143 30.6 110 76.9 33 23.1
SCC 242 51.7 181 74.8 61 25.2 ns
ADCA 226 48.3 172 76.1 54 23.9
pT1 98 20.9 78 79.6 20 20.4 ns
pT2 256 54.7 195 76.2 61 23.8
pT3 69 14.7 50 72.5 19 27.5
pT4 45 9.6 30 66.7 15 33.3
pN0 244 52.1 186 76.2 58 23.8 ns
pN1 142 30.3 110 77.5 32 22.5
pN2 72 15.4 51 70.8 21 29.2
pN3 10 2.1 6 60 4 40
pM0 430 91.9 330 76.7 100 23.3 0.031/
pM1 38 8.1 23 60.5 15 39.5 0.1
G1 28 6 22 78.6 6 21.4 ns
G2 245 52.3 187 76.3 58 23.7
G3 195 41.7 144 73.8 51 26.2
Size < 3.7cm 241 51.5 189 78.4 52 21.6 ns
Size ≥ 3.7cm 227 48.5 164 72.2 63 27.8
No vessel infiltration 249 53.2 197 79.1 52 20.9 0.036/
Vessel infiltration 219 46.8 156 71.2 63 28.8 0.09
Neg. negative, pos. positive, ns not significant, tau correlation coefficient
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Figure 1 Expression of L1CAM in NSCLC. A/B) SCC with expression of L1CAM (*) whereas the bronchial ciliated and focally metaplastic
epithelium is negative (**), magnification 200x. Note on Figure 1B the pronounced expression of L1CAM in some areas of the tumor-stroma
interface. C/D) Serial section, C CD31 (endothelial cells marked by arrowheads) and D L1CAM, of a SCC surrounding and partially invading the
media of a blood vessel. Note that intratumoral vessels regularly show profound remodeling of the arteriolar wall with disappearance of the
elastic layers normally bordering the media myocytes, magnification 200x. E) L1CAM positive tumor cells (brown) destroying the vessel wall lined
by CD31 positive (red) endothelial cells. F) Accentuated L1CAM expression at the tumor-stroma interface (dashed line) and weaker
(heterogeneous) L1CAM expression in the lower part of the picture representing a central part of the tumor. Hematoxylin counterstain was used
for all slides.
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Figure 2 L1CAM and EMT marker expression patterns at the tumor-stroma interface. A) SCC with expression of L1CAM at the tumor-
stroma interface (brown). The tumor center shows moderate E-cadherin expression (red). At the tumor-stroma interface, E-cadherin expression is
decreased. Note the strong positivity of small peripheral nerves for L1CAM. B) Double IF staining for L1CAM (green) and E-cadherin (red): L1CAM
is expressed at the tumor border and E-cadherin expression is strongest in the tumor center. E-cadherin expression is decreased at the tumor
border (yellow). C) Membranous E-cadherin (red) is expressed in the tumor center and decreased towards the tumor-stroma interface. Two
strong Vimentin positive (brown) stromal cell aggregates are marked with dotted lines (upper left and mid to lower right). Note that most of the
Vimentin positive cells show nuclear morphology of the tumor cells. CD68 staining to exclude Vimentin positive macrophages was not
performed. D) Decrease of membranous E-cadherin (red) and strong nuclear expression of slug (brown) at the tumor-stroma interface of a SCC.
In the tumor center E-cadherin is strongly but slug is not expressed (blue nuclei). Hematoxylin and DAPI counterstain were used, respectively.
Tumor-stroma interfaces are marked by dotted lines.
Table 2 Univariate cumulative survival analysis (54 months)
Survival L1CAM
expression
Cases Events Estimate 95% CI
lower
95% CI
upper
p-value
OS negative 346 245 69.32 62.81 75.82 < 0.001
positive 106 83 46.23 36.77 55.69
PFS negative 346 254 61.2 54.46 67.95 < 0.001
positive 106 87 37.43 27.88 46.98
OS overall survival, PFS progression free survival, CI confidence interval
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data on L1CAM expression in extrahepatic cholangiocar-
cinoma, gastric, breast, colorectal, ovarian, endometrial,
and pancreatic duct carcinoma [6,21,26-30].
We observed a negative correlation of L1CAM with E-
cadherin and a positive correlation with slug/vimentin/
beta-catenin, indicating a potential role of L1CAM in
EMT of NSCLC. Our results are in concordance with
findings in colorectal, breast and pancreatic carcinoma
where L1CAM expression was clearly involved in the
EMT program [9,16,23]. It is unclear how L1CAM up-
regulation exactly occurs in NSCLC. Several mechanisms
have been described so far: In colorectal carcinoma, aber-
rant L1CAM expression was attributed to a hyperactive
beta-catenin/TCF pathway [23] or to DNA hypomethyla-
tion at CpG islands of the L1CAM promoter [31]. In a
pancreatic cancer cell line L1CAM expression was regu-
lated via binding of the transcription factor slug to the
L1CAM promoter, induced by TGF-beta1 and mediated
by c-jun NH2-terminal kinase [9].
In A549 cells, L1CAM expression was inducible by
TGF-beta1 which also induced beta-catenin and vimen-
tin and downregulated E-cadherin. We found the EMT
transcription factors slug and snail induced by TGF-
beta1 on the mRNA level. Our results would favor a
model in which aberrant L1CAM expression in NSCLC
is mediated by slug and an activated beta-catenin path-
way. A knockdown of slug or snail was not performed
so that we cannot prove this hypothesis. L1CAM knock-
down in the cell lines SK-LU-1 and SK-LC-LL reduced
matrigel invasion but we did not observe further up-reg-
ulation of L1CAM expression by TGF-beta1 in the latter
cell lines.
Recently, EMT has been linked to the cancer stem cell
(CSC) phenotype [32], and L1CAM was shown to be co-
expressed with the CSC marker CD133 in glioma cells
[33]. Molecular targeting of L1CAM in CD133+ glioma
cells reduced tumor growth and increased survival in-vivo
[33]. In a widely accepted hypothesis CSC’s are believed to
be endowed with increased drug resistance [34]. The exis-
tence of bronchoalveolar stem cells (BASC’s) and their key
role in KRAS-induced lung cancer was proven although it
is not assured that BASC’s can induce a histophenocopy
of the initial tumor in secondary or tertiary hosts (for
review see [34]). It remains to be seen if the dismal prog-
nosis that we observe in the L1CAM positive NSCLC sub-
group is related to the presence of CSC’s.
We observed a correlation of L1CAM protein up-
regulation with blood vessel invasion and metastasis in
NSCLC. Further, L1CAM was accentuated at the
tumor-stroma interface but decreased in central parts,
suggesting an L1CAM involvement in tumor cell inva-
sion. SiRNA knockdown of L1CAM conferred a less
invasive phenotype in the two cell lines tested, support-
ing our in-vivo observation. On whole sections, we
found strong L1CAM expression of tumor cells close to
and inside intratumoral blood vessels. Up-regulation of
L1CAM at the invasive front was also found in colorec-
tal cancer [23]. NSCLC has a highly desmoplastic
stroma similar to pancreatic duct carcinoma, often with
formation of a central scar. It is unclear whether this
prominent fibrotic reaction is inhibiting or rather pro-
moting tumor cell migration. Therefore the question
arises whether up-regulation of L1CAM is a prerequisite
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Figure 3 L1CAM expression is correlated with shortened
overall survival.
Table 3 Multivariate survival analysis
Parameters p-value Exp(B) 95% CI
lower
95% CI
upper
OS
L1CAM 0.043 1.31 1.01 1.7
pT < 0.001 1.47 1.29 1.68
pN 0.001 1.26 1.1 1.45
pM < 0.001 3.51 2.41 5.09
Grade 0.03 1.23 1.02 1.48
PFS
L1CAM 0.022 1.34 1.04 1.73
pT < 0.001 1.57 1.37 1.79
pN 0.011 1.2 1.04 1.38
pM < 0.001 5.81 3.82 8.82
Grade 0.018 1.25 1.04 1.49
OS overall survival, PFS progression free survival, exp(B) instantaneous relative
risk of an event if parameter is present, CI confidence interval
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for infiltrating tumor cells to reach and invade neo-
angiogenetic blood vessels. This hypothesis requires
further systematic investigation by in-vitro and in-vivo
vessel invasion assays. Two recent studies showed that a
soluble form of L1CAM acts pro-angiogenic and
L1CAM expression in the tumor endothelium mediates
selective tumor cell transmigration in pancreatic adeno-
carcinoma [35,36].
Anti-L1CAM therapy altered L1CAM gene expression
in-vitro as well as reduced tumor growth in a mouse
model of intraperitoneally transplanted ovarian cancer
cells [37-40]. Thus, anti-L1CAM agents may be used in
the setting of intracavitary chemotherapy of malignant
effusions. Since protein expression in the carcinoma cells
was of similar intensity compared with adjacent peripheral
nerves and proximal tubules of the kidney, systemic ther-
apy with mAb to L1CAM could potentially lead to neuro-
logical or renal complications.
Conclusions
We demonstrate that the cell adhesion molecule L1CAM
is aberrantly expressed in a subset of NSCLC and inde-
pendently prognostic for poor survival. Further, we show
that L1CAM expression is induced by TGFbeta1 and that
siRNA knockdown of L1CAM reduces matrigel invasion.
The mechanism by which L1CAM leads to a more
aggressive tumor phenotype is potentially related to EMT
in-vivo and in-vitro. A targeted tumoral anti-L1CAM
therapy could support anti-epidermal growth factor
receptor or anti-vascular endothelial growth factor inhi-
bition in NSCLC.
Materials and methods
Patient cohort
Tumor tissue of 472 consecutive patients with surgically
resected primary NSCLC between 1993 and 2002 including
244 squamous cell carcinomas (SCC; 51.7%) and 228 ade-
nocarcinomas (ADCA; 48.3%) was used for construction of
a tissue microarray (TMA). Briefly, each patient’s tumor
was represented by two 0.6mm cores. Histotypes like large
cell, adeno-squamous, neuroendocrine or sarcomatoid car-
cinoma, metastases or relapsing tumors and neo-adjuvantly
treated patients were not included. Histotypes were entirely
reviewed on H&E and mucin stained sections and con-
trolled by IHC according to recent recommendations [41].
Presence of blood vessel infiltration was identified on H&E
and Elastica-Van-Gieson stained whole sections. Progres-
sion-free (PFS) and overall (OS) survival data was available
for 456 patients. The mean follow-up time was 43 (range
0-169, median 25) and 51 months (range 1-169 months,
median 41) for PFS and OS, respectively. The study was
approved by the ethical committee of the Kanton of Zurich
(reference number StV-29-2009).
Immunohistochemistry and -fluorescence
Immunohistochemistry (IHC) of TMA sections was per-
formed using the following primary antibodies: mAb
anti-E-cadherin (Cell Marque Lifescreen Ltd., Rocklin,
CA, USA, clone EP700Y, 1:200), mAb anti-beta-catenin
(BD Transduction laboratories, Lexington, KY USA,
clone 14/beta-catenin, 1:50), mAb anti-vimentin (DAKO
A/S, Glostrup, Denmark, 1:250), and mAb anti-slug (Cell
Signaling Technology, Inc, Danvers, MA, USA, clone
C19G7, 1:100). MAb anti-L1CAM (clone 14.10, directed
to the ectodomain, 1:200) was generated as described
[24]. Antibodies were tested on a multi tissue TMA for
appropriate dilutions. Two protocols were applied: First,
on a Ventana Benchmark® platform (Ventana Medical
Systems, Tucson, AZ, USA), the CC1 standard pretreat-
ment with 60 min boiling in pH 8 Tris buffer was fol-
lowed by incubation with primary mAb (E-cadherin,
beta-catenin, vimentin) for 60 min at room temperature
(RT) and development with the Ultraview-HRP kit,
including incubation with respective secondary ab for 30
min at RT. Second, on a Leica Bond® platform (Vision
Biosystems, Melbourne, Australia), the H2 standard pre-
treatment with 60 min boiling in pH8 Tris buffer was fol-
lowed by incubation with primary mAb (L1CAM, slug)
for 30 min at RT and development with the Refine-DAB
Bond kit, including incubation with secondary ab for
30 min at RT and additional polymer amplification. All
primary antibodies were diluted in Tris/BSA. To visualize
the topographic distribution of protein expression, repre-
sentative whole sections (n = 5) were stained with double
IHC or double IF. For IHC, the Leica Bond® platform
with Bond Polymer AP Red Detection and Polymer
Refine Detection kits was used. For both systems, hema-
toxylin counterstain was applied. For IF, sections were
boiled for 20 min in citrate buffer and blocked with 5%
goat serum for 10 min and incubated overnight with first
mAb at 4°C. After washings, slides were probed with an F
(ab) goat anti-mouse Alexa-488 (spectrum green, 1:100)
Table 4 Correlation of L1CAM with EMT markers
Slug Beta-catenin E-cadherin Vimentin
(nuc) (mem) (cyto) (nuc) (mem) (cyto) (stroma)
L1CAM p < 0.05 ns 0.001 ns 0.001 < 0.001 0.001
(mem) tau 0.101 -0.073 0.136 0.036 -0.139 0.249 0.137
p p-value, tau correlation coefficient, nuc nucleus, mem membrane, cyto cytoplasm
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Figure 4 L1CAM in A549. A) Stimulation of A549 cells with TGF-beta1 induces a mesenchymal phenotype whereas HGF does not alter cell
morphology. Note that TGF-beta1 treatment affected the proliferation of A549 cells. B/C) A549 cells stimulated with TGF-beta1 show an EMT
phenotype and increased L1CAM expression on mRNA and protein level. One representative experiment of n = 3 is shown. GAP-DH loading
control. D) Matrigel invasion of A549 cells is enhanced by TGF-beta1 stimulation. The error bars represent mean values ± SEM. One
representative experiment of n = 3 is shown.
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or Alexa-546 (spectrum orange, 1:100) for 45 min and
counterstained with DAPI. Pictures were taken on an
Olympus microscope with CCD camera using the Analy-
SIS software (Olympus, Munster, Germany).
Intensity of immunoreactivity was semi-quantitatively
scored, applying a four-tiered system (0 to 3). L1CAM
was independently scored by two pathologists (VT&SH;
interobserver kappa-value 0.78). Both scores showed
similar results in correlation with EMT markers and
clinicopathological parameters. One score (VT) is
shown. Peripheral nerves served as internal positive con-
trol for L1CAM staining. For L1CAM and E-cadherin
membranous staining was counted (score 0 negative,
score 1 faint discontinuous, score 2 moderate continu-
ous, score 3 strong continuous). Beta-catenin was sepa-
rately scored at the plasma membrane, the cytoplasm
and the nucleus. Slug was scored in the nucleus. Vimen-
tin was scored in the tumor cell cytoplasm and in
peritumoral stromal cells. The two TMA cores were
summed up to the sum intensity score (range 0-6).
Cell culture
The lung carcinoma cell lines A549 (ADCA; obtained
from ATCC, #CCL-185), SK-LU-1 (ADCA; obtained
from ATCC, #HTB-57), H1395 and SK-LC-LL (ADCA
and SCC, respectively; obtained from Dr. Reinhard
Schwartz-Albiez, DKFZ Heidelberg) were cultivated in
RPMI-1640 medium supplemented with 10% fetal bovine
serum and 10 mM Glutamine at 37°C, 5% CO2 and 100%
humidity. Cells were periodically tested by PCR for
mycoplasma. For induction of EMT cells were cultivated
in the presence of HGF (Promokine, Heidelberg, Ger-
many) 5 ng/ml or TGF-beta1 (Promokine, Heidelberg,
Germany) 10 ng/ml for 7 days.
Quantitative real-time PCR
qRT-PCR was performed as described before [21]. Primers
for qRT-PCR were designed using the IDT primer quest
programme and were produced by MWG (Ebersberg,
Germany). Beta-actin was used as an internal standard.
The sequences of primers used are available on request.
Western blot
SDS-PAGE under non-reducing conditions and transfer of
proteins to an Immobilon membrane using semi-dry blot-
ting has been described previously [42]. After blocking
with 5% skimmed milk in TBS, the blots were developed
with the respective primary antibody as described [21], fol-
lowed by peroxidase-conjugated secondary antibody and
ECL (Perkin-Elmer, Rodgau, Germany) detection. The
mAbs used for Western blot analysis were described
before [21].
L1CAM knockdown
For siRNA mediated knockdown, either siGFP or siL1-
CAM were used. Sequences have been published before
[43]. Cells were transfected with Oligofectamine (Invi-
trogen, Karlsruhe, Germany) 24 h before onset of the
Matrigel invasion assay.
Matrigel invasion assay
Tumor cell invasion in-vitro was determined in a double-
filter assay. Briefly, Matrigel was layered between two fil-
ters, including a lower 5-μm pore nitrocellulose and an
upper 8-μm pore polycarbonate filter. The lower filter was
fixed by a gel that consisted of human fibrinogen (5 mg/
mL) and casein (5 mg/mL) dissolved in serum-containing
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Figure 5 SiRNA knockdown reduces matrigel invasion. A) SiRNA
knockdown suppresses L1CAM expression in SK-LU-1 and SK-LC-LL
cells. B) L1CAM siRNA knockdown significantly reduces matrigel
invasion of SK-LU-1 and SK-LC-LL cells. The error bars represent mean
values ± SEM. One representative experiment of n = 3 is shown.
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culture medium. 105 cells were incubated with the filter
sandwich for 20 h in 1 mL of medium. The next day, the
sandwich was fixed and the filters separated and DAPI
stained. Cells attached to the lower filter were counted,
and cell invasion was expressed as the ratio of the cell
number on the lower filter to the total number of cells in
a proliferation control. Five sections per filter were photo-
graphed using a Zeiss fluorescence microscope and
counted using Image J software.
Statistics
PFS time was defined as the interval between surgery
and disease progression, death or last contact, respec-
tively. Only documented relapses were accepted for war-
ranting progression. Patients with initial metastatic
disease were considered to have PFS = 0. OS time was
defined as the interval between surgery and death or
last contact, respectively. In case of one core loss, data
from the remaining core was carried forward. If both
cores were not evaluable (4 patients), the case was
excluded (n final = 468). Correlations of protein expres-
sion intensities with clinico-pathologic parameters were
calculated by Kendall’s tau b analysis, with PFS and OS
by the Kaplan-Meier method using log rank tests. The
median value of the sum score was used as cut-off point
for dichotomization into a “L1CAM negative” and
“L1CAM positive” group. All cases which did not show
equal staining intensity for both cores were counted as
heterogeneous. Significant univariate prognostic factors
were introduced into multivariate analysis applying Cox
proportional hazards regression. Statistical analyzes were
performed using PASW, version 18.0. P-values < 0.05
were considered significant. Statistical significance of the
cell culture experiments was determined by Student’s
t test. P-values in Figure 4 are indicated as follows:
*< 0.05, **< 0.01 ***< 0.001.
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